| Browse All

Immunome, Inc. (IMNM)

Healthcare | Biotechnology | Bothell, United States | NasdaqCM
24.63 USD +1.37 (5.890%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 24.65 +0.02 (0.081%) ⇧ (April 17, 2026, 7:04 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:57 p.m. EDT

IMNM presents a mixed picture with a high overall risk and negative earnings, suggesting significant volatility and uncertainty. The recent price movements show some momentum, but the lack of consistent dividends and negative fundamentals make it a risky proposition. The options activity indicates that traders are speculative, but the overall forecast model suggests a modest upward trend with limited reliability. Investors should proceed with caution, considering the high risk and uncertain fundamentals.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.092372
AutoTheta0.092701
AutoARIMA0.092911
MSTL0.098815

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 50%
H-stat 3.93
Ljung-Box p 0.000
Jarque-Bera p 0.188
Excess Kurtosis -0.64
Attribute Value
Sector Healthcare
Debt to Equity Ratio 0.608
Revenue per Share 0.079
Market Cap 2,786,470,656
Forward P/E -11.65
Beta 2.14
Website https://immunome.com

As of April 11, 2026, 3:57 p.m. EDT: The options data indicates a mix of speculation and volatility. The ATM IV is relatively high, suggesting increased uncertainty or expectations of price movement. The significant strikes show a concentration of both calls and puts around the current price, indicating that traders are hedging or anticipating a move. The presence of high IV spikes and significant OI in out-of-the-money strikes suggests that there is a lot of speculation around potential price swings. However, the overall trend in options activity does not clearly indicate a strong bullish or bearish sentiment, and the high volatility could be a sign of uncertainty.


Info Dump

Attribute Value
52 Week Change 2.07875
Address1 18,702 North Creek Parkway
Address2 Suite 100
All Time High 63.78
All Time Low 2.09
Ask 27.35
Ask Size 2
Audit Risk 6
Average Analyst Rating 1.1 - Strong Buy
Average Daily Volume10 Day 1,040,130
Average Daily Volume3 Month 1,345,417
Average Volume 1,345,417
Average Volume10Days 1,040,130
Beta 2.14
Bid 17.78
Bid Size 2
Board Risk 8
Book Value 5.607
City Bothell
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 10
Country United States
Crypto Tradeable 0
Currency USD
Current Price 24.63
Current Ratio 14.687
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 24.81
Day Low 23.53
Debt To Equity 0.608
Display Name Immunome
Earnings Timestamp 1,772,571,600
Earnings Timestamp End 1,778,616,000
Earnings Timestamp Start 1,778,616,000
Ebitda -211,647,008
Ebitda Margins 0.0
Enterprise To Ebitda -10.096
Enterprise To Revenue 307.858
Enterprise Value 2,136,843,648
Eps Current Year -2.37077
Eps Forward -2.11364
Eps Trailing Twelve Months -2.43
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 21.8722
Fifty Day Average Change 2.7577991
Fifty Day Average Change Percent 0.12608695
Fifty Two Week Change Percent 207.87498
Fifty Two Week High 27.65
Fifty Two Week High Change -3.0200005
Fifty Two Week High Change Percent -0.10922244
Fifty Two Week Low 7.15
Fifty Two Week Low Change 17.48
Fifty Two Week Low Change Percent 2.444755
Fifty Two Week Range 7.15 - 27.65
Financial Currency USD
First Trade Date Milliseconds 1,601,645,400,000
Float Shares 94,305,572
Forward Eps -2.11364
Forward P E -11.652883
Free Cashflow -133,619,624
Full Exchange Name NasdaqCM
Full Time Employees 177
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Gross Profits -170,344,992
Has Pre Post Market Data 1
Held Percent Insiders 0.07481
Held Percent Institutions 1.03116
Implied Shares Outstanding 113,133,199
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,020-10-02
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Long Name Immunome, Inc.
Market us_market
Market Cap 2,786,470,656
Market State CLOSED
Max Age 86,400
Message Board Id finmb_108518404
Most Recent Quarter 1,767,139,200
Net Income To Common -212,394,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,786,470,691
Number Of Analyst Opinions 13
Open 23.85
Operating Cashflow -190,919,008
Operating Margins -30.84757
Overall Risk 10
Payout Ratio 0.0
Phone 425 939 7410
Post Market Change 0.020000458
Post Market Change Percent 0.08120365
Post Market Price 24.65
Post Market Time 1,776,467,074
Previous Close 23.26
Price Eps Current Year -10.3890295
Price Hint 2
Price To Book 4.3927236
Price To Sales Trailing12 Months 401.4509
Profit Margins 0.0
Quick Ratio 14.525
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.14286
Region US
Regular Market Change 1.37
Regular Market Change Percent 5.88994
Regular Market Day High 24.81
Regular Market Day Low 23.53
Regular Market Day Range 23.53 - 24.81
Regular Market Open 23.85
Regular Market Previous Close 23.26
Regular Market Price 24.63
Regular Market Time 1,776,456,001
Regular Market Volume 991,458
Return On Assets -0.28983
Return On Equity -0.52089
Revenue Growth -1.0
Revenue Per Share 0.079
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 113,133,199
Shares Percent Shares Out 0.1675
Shares Short 18,945,536
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 17,887,518
Short Name Immunome, Inc.
Short Percent Of Float 0.1731
Short Ratio 12.26
Source Interval 15
State WA
Symbol IMNM
Target High Price 40.0
Target Low Price 30.0
Target Mean Price 35.53846
Target Median Price 36.0
Total Cash 653,481,984
Total Cash Per Share 5.776
Total Debt 3,855,000
Total Revenue 6,941,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.43
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 16.895325
Two Hundred Day Average Change 7.7346745
Two Hundred Day Average Change Percent 0.4577997
Type Disp Equity
Volume 991,458
Website https://immunome.com
Zip 98,011